Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Trifluridine-tipiracil hydrochloride
Synonyms
Therapy Description

Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth (PMID: 29226002). Lonsurf (trifluridine/tipiracil hydrochloride) is FDA-approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma, and in combination with Avastin (bevacizumab) in patients with previously-treated metastatic colorectal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Trifluridine-tipiracil hydrochloride Lonsurf TAS-102|TAS102|TAS 102|S 95005|S95005|S-95005 Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth (PMID: 29226002). Lonsurf (trifluridine/tipiracil hydrochloride) is FDA-approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma, and in combination with Avastin (bevacizumab) in patients with previously-treated metastatic colorectal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06356311 Phase III Trifluridine-tipiracil hydrochloride Irinotecan Paclitaxel Docetaxel SKB264 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Recruiting USA 2
NCT05062889 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC) Recruiting ITA 0
NCT05201352 Phase Ib/II Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride + XB2001 Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1alpha True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN) Recruiting FRA 0
NCT04776148 Phase III Regorafenib Trifluridine-tipiracil hydrochloride Lenvatinib + Pembrolizumab Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) Active, not recruiting USA | GBR | ESP | DEU | CAN | AUS 9
NCT01607957 Phase III Trifluridine-tipiracil hydrochloride Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 4
NCT03992456 Phase II Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Active, not recruiting USA 0
NCT04489173 Phase II Trifluridine-tipiracil hydrochloride TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET) Active, not recruiting NLD 0
NCT04073615 Phase Ib/II Rivoceranib + Trifluridine-tipiracil hydrochloride Rivoceranib Trifluridine-tipiracil hydrochloride Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer Terminated USA 0
NCT03520946 Phase III Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) Active, not recruiting DEU 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Active, not recruiting USA | ITA | ESP | DEU | AUT | AUS 3
NCT06346392 Phase III Rivoceranib Trifluridine-tipiracil hydrochloride Paclitaxel + Ramucirumab Docetaxel Paclitaxel Irinotecan AZD0901 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 7
NCT01916447 Phase I Bevacizumab Trifluridine-tipiracil hydrochloride Irinotecan A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. Completed USA 0
NCT04737187 Phase III Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT03981614 Phase II Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Active, not recruiting USA 0
NCT02602327 Phase I Trifluridine-tipiracil hydrochloride Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases Completed USA 0
NCT04042714 Phase II Trifluridine-tipiracil hydrochloride TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (TAS-102 NEC) Unknown status USA 0
NCT03762161 Phase II Trifluridine-tipiracil hydrochloride A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer Unknown status USA 0
NCT02500043 Phase III Trifluridine-tipiracil hydrochloride Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 10
NCT02301117 Phase I Trifluridine-tipiracil hydrochloride A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment Completed USA 2
NCT03844620 Phase II Regorafenib Trifluridine-tipiracil hydrochloride Regorafenib + Trifluridine-tipiracil hydrochloride Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT04854434 Phase II Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations Terminated USA 0
NCT05223673 Phase III Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) Terminated USA | BEL 4


Additional content available in CKB BOOST